Literature DB >> 7767314

Synthesis of radioiodinated analogs of 2-(4-phenylpiperidino)cyclohexanol (vesamicol) as vesamicol-like agent.

K Shiba1, H Mori, H Matsuda, S Tsuji, I Kuji, H Sumiya, K Kinuya, N Tonami, K Hisada, T Sumiyosi.   

Abstract

Three iodovesamicol analogs, iodinated at the ortho, meta, and para positions of the 4-phenylpiperidine moiety, were synthesized and labeled with 125I by isotopic exchange reaction. Their potencies as a vesamicol-like drug were evaluated with competitive inhibition studies using (-)[3H]vesamicol. The radiochemical yields were 40-85%, the radiochemical purities exceeded 95% and their specific activities were 370-740 GBq/mmol. The descending order of binding affinity of the tested compounds against the vesamicol receptor was m-iodovesamicol > o-iodovesamicol > p-iodovesamicol. The receptor binding affinity of m-iodovesamicol (IC50 = 133 nM) was comparable with that of vesamicol (IC50 = 109 nM). Therefore, the meta position of the 4-phenylpiperidinyl fragment of vesamicol was the optimum site for iodination, and radioiodinated m-iodovesamicol may serve as a useful radiopharmaceutical for in vitro and in vivo studies of presynaptic cholinergic neurons in rats.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767314     DOI: 10.1016/0969-8051(94)00093-y

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  2 in total

1.  Development of tumor-targeting aza-vesamicol derivatives with high affinity for sigma receptors for cancer theranostics.

Authors:  Kenji Mishiro; Mengfei Wang; Saki Hirata; Takeshi Fuchigami; Kazuhiro Shiba; Seigo Kinuya; Kazuma Ogawa
Journal:  RSC Med Chem       Date:  2022-06-30

2.  Development and evaluation of a novel radioiodinated vesamicol analog as a sigma receptor imaging agent.

Authors:  Kazuma Ogawa; Hiroya Kanbara; Kazuhiro Shiba; Yoji Kitamura; Takashi Kozaka; Tatsuto Kiwada; Akira Odani
Journal:  EJNMMI Res       Date:  2012-09-28       Impact factor: 3.138

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.